Mariner’s Vyant Bio, Inc. Common Stock VYNT Stock Holding History

Mariner’s Portfolio VYNT Stock Details VYNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-2,055	Closed	-$6K	–	2873
2022 Q3	$6K	Buy	+2,055	New	+$7.76K	﹤0.01%	2430

Other funds holding VYNT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

Mariner's VYNT Position: Q4 2022 in Review

Mariner sold out of Vyant Bio, Inc. Common Stock (VYNT) in Q4 2022, closing a stake of 2,055 shares — an estimated $6K sold.

Mariner first reported a position in VYNT in Q3 2022 and held it in 1 quarter. The position peaked at $6K in Q3 2022. 17 funds tracked by Wall St. Rank hold VYNT as of Q4 2022.

Mariner reported no remaining Vyant Bio, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Mariner sold 2,055 Vyant Bio, Inc. Common Stock shares in Q4 2022, an estimated $6K.
Mariner first reported a position in Vyant Bio, Inc. Common Stock in Q3 2022 and held it in 1 quarter.
Mariner's Vyant Bio, Inc. Common Stock position peaked at $6K in Q3 2022.
17 funds tracked by Wall St. Rank held Vyant Bio, Inc. Common Stock as of Q4 2022.

Based on Mariner's 13F filing for Q4 2022, filed 14 Feb 2023.